MedTrace Logo

Effect of Metformin on Visual Function in Patients With Glaucoma

NCT04155164 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-02-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether Metformin could prevent the progression of glaucoma in a safe and effective manner.

Conditions

  • Primary Open Angle Glaucoma

Interventions

DRUG

Metformin

Participants will receive Metformin at 1000mg for 12 months.

DRUG

Placebos

Placebo group will take Placebo at 1000mg for 12 months.

Sponsors & Collaborators

  • Zhongshan Ophthalmic Center, Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Xialin Liu, Prof. · Zhongshan Ophthalmic Center, Sun Yat-sen University

  • Xing Liu, Prof. · Zhongshan Ophthalmic Center, Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-10
Primary Completion
2022-05-31
Completion
2024-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04155164 on ClinicalTrials.gov